Maia Biotechnology, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
AMEX
MAIA Biotechnology, Inc. reports that Director Steven M. Chaouki acquired stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
Ramiro Guerrero, a Director at MAIA Biotechnology, Inc., acquired 26,355 stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology, Inc. reports that Director Cristian Luput acquired 27,610 stock options on June 30, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology, Inc. reports that Director Stan Smith acquired stock options representing 32,003 shares of common stock.
AMEX
MAIA Biotechnology, Inc. reports that Director Jean-Manasse Theagene was granted stock options for 26,355 shares.
AMEX
MAIA Biotechnology, Inc. reports a significant stock purchase by CEO Vlad Vitoc, increasing his direct beneficial ownership.
AMEX
Director Stan Smith reported the acquisition of 75,000 shares of MAIA Biotechnology, Inc. common stock on June 1, 2026.
AMEX
MAIA Biotechnology's Chief Scientific Officer, Sergei Gryaznov, acquired 2,000 shares of common stock on June 1, 2026, at a price of $1.345 per share.
AMEX
MAIA Biotechnology reports a significant stock option grant to CEO Vlad Vitoc, reflecting a long-term incentive structure.
AMEX
MAIA Biotechnology, Inc. reports a significant stock option grant to Chief Scientific Officer Sergei Gryaznov.
AMEX
MAIA Biotechnology, Inc. reports that Head of Finance, Jeffrey C. Himmelreich, acquired 60,000 stock options on May 29, 2026.
AMEX
MAIA Biotechnology's CEO, Vlad Vitoc, reports the acquisition of 800,000 stock options with an exercise price of $1.28, vesting over four years.
AMEX
Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., was granted 400,000 stock options with an exercise price of $1.28.
AMEX
MAIA Biotechnology, Inc. reports that Head of Finance, Jeffrey C. Himmelreich, acquired 30,000 stock options on April 10, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology, Inc. reports that Director Steven M. Chaouki acquired 27,907 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
Ramiro Guerrero, a Director at MAIA Biotechnology, Inc., acquired 27,258 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
Louie Ngar Yee, a Director at MAIA Biotechnology, Inc., acquired 33,748 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology, Inc. reports that Director Cristian Luput acquired 28,556 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology, Inc. reports that Director Jean-Manasse Theagene acquired 27,258 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.
AMEX
Stan Smith, a Director at MAIA Biotechnology, Inc., acquired 33,099 stock options on March 31, 2026, as detailed in a recent SEC Form 4 filing.
AMEX
MAIA Biotechnology Director Stan Smith reported recent acquisitions of common stock, increasing his indirect beneficial ownership.
AMEX
MAIA Biotechnology Director Jean-Manasse Theagene was granted 24,060 stock options exercisable at $1.53 per share, vesting immediately.
AMEX
MAIA Biotechnology Director Stan Smith was granted 29,216 stock options at an exercise price of $1.53, vesting immediately.
AMEX
MAIA Biotechnology, Inc. Director Cristian Luput was granted 25,206 stock options exercisable at $1.53 per share, vesting immediately.
AMEX
MAIA Biotechnology Director Ngar Yee Louie reported the acquisition of 29,789 stock options exercisable at $1.53 per share, granted under the company's 2021 Equity Incentive Plan.
AMEX
MAIA Biotechnology Director Ramiro Guerrero was granted 24,060 stock options with an exercise price of $1.53, vesting immediately.
AMEX
MAIA Biotechnology Director Steven M. Chaouki acquired 24,633 stock options with an exercise price of $1.53, vesting immediately.
AMEX
MAIA Biotechnology Director Stan Smith acquired 57,189 shares of common stock and 57,189 stock options, signaling increased insider confidence.
AMEX
MAIA Biotechnology Director Steven M. Chaouki acquired 40,849 shares of common stock and 40,849 stock options on December 22, 2025, increasing his direct beneficial ownership.
AMEX
MAIA Biotechnology Director Ngar Yee Louie acquired common stock and stock options on December 22, 2025, increasing her beneficial ownership.